GenScript ProBio developed the distinguishing Phase-appropriate Compliance (PAC) quality system to meet worldwide stringent regulatory standards (including US-FDA/EU-EMA/China-NMPA), which will benefit our customers in a way of high quality, cost-effectiveness, efficiency and credibility.
GenScript ProBio Congratulates XLifeSc on FDA Allowance of for IND Application for TCR-T Program Learn More »
GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc. Learn More »
GenScript ProBio American Commercial Head, Kenneth Lee gives interview to The Medicine Maker about How we can help customers optimize their developing and manufacturing processesLearn More »
Beroni Group Signs Agreement with GenScript ProBio to Conduct Further Study to Develop Nanobody-based Medical Solution for COVID-19Learn More »
GenScript ProBio is the bio-pharmaceutical CDMO segment of GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.
GenScript ProBio’s innovative solutions for antibody drug development include antibody drug discovery, antibody engineering and antibody characterization. In terms of biologics development service, GenScript ProBio has built a regulatory-compliant platform, from stable cell line development to clinical manufacturing services, providing high quality material for IND and clinical trials. GenScript ProBio’s total gene and cell therapy solution covers CMC of plasmid and virus for IND filing as well as clinical manufacturing and commercial manufacturing.
Toward the mission of “Innovation through Collaboration”, GenScript ProBio is committed to helping customers significantly lower R&D costs and building a healthier future.